36 Putting cancer on the global agenda Financial Report Report of the Treasurer and the Chair of the Finance Committee The International Union Against Cancer (UICC) records its income and expenditure in two distinct accounts. Unrestricted funds relate primarily to the operations of the UICC Secretariat and are accounted in Swiss Francs. Restricted funds are designated for specific UICC programmes and are expressed in US Dollars. For reporting purposes, the two sets of accounts are consolidated into one combined financial statement expressed in US Dollars. The accounts for 2005 were audited by Deloitte SA, who are satisfied that the accounting records and the financial statements comply with Swiss laws and UICC s articles of incorporation and recommend that the financial statements be approved (see page 38). Income Total unrestricted and restricted income in 2005 amounted to US$ 6,893,877, compared with US$ 4,917,810 in 2004. Unrestricted income, which mainly covers the operations of the UICC Secretariat, increased modestly in dollar terms, from US$ 2,066,490 in 2004 to US$ 2,154,091 in 2005, but remained stable when expressed in Swiss Francs. Dues from UICC members remained practically unchanged Dr Louis Jean Denis (Belgium), Treasurer 12% at US$ 1,133,654. During 2005, seven members cancelled their memberships and 15 organisations joined UICC. At the end of 2005, membership stood at 268. Significant income for the unrestricted accounts was generated from royalties of US$ 500,000 from the International Journal of Cancer, which is published by John Wiley and Sons on behalf of UICC, and from Wiley s corporate membership and other related income, which provided an additional US$ 195,000 in 2005. 3% 13% Strategic programmes Campaigns Mr John C Baity (USA), Chair, Finance Committee Figure 1 Communications Cancer Journal Restricted income, which is designated for specific programmes, grew strongly, from US$ 2,851,320 in 2004 to US$ 4,739,786 in 2005. The principal reason for this increase was the funding received for the newly launched My Child Matters campaign. Other programmes also attracted significant additional income. Expenditure Unrestricted expenditure related to UICC s operational costs remained slightly below the previous year s level at US$ 2,141,829. This resulted in a modest surplus of US$ 12,262 on the unrestricted accounts. Restricted expenditure related to specific programmes amounted to US$ 3,810,363 in 2005, compared with US$ 3,126,029 in 2004, reflecting the increase in restricted income for the reporting period. In 2005, restricted expenditure was spread over different UICC activities as shown in Figure 1. Fund balance 72% The stable operational result in unrestricted income and expenditure is reflected in a stable balance in the unrestricted funds and reserves combined. As instructed by the Executive Committee, in 2005 UICC again increased its statutory reserves by US$ 50,000,
Putting cancer on the global agenda 37 which was allocated from the fund balance. In addition, UICC maintained a special provision of CHF 300,000 for the planned relocation of its office in Geneva in 2006. The restricted fund balance increased significantly from US$ 1,559,032 at year end 2004 to US$ 2,488,454 at year end 2005. The restricted funds are accounted on a cash basis and there can therefore be significant time lags between receiving funds and disbursing them for the designated programmes. The Finance Committee would like to thank UICC member organisations for their continued loyal support. We particularly appreciate the support of those members who have provided contributions well in excess of the statutory annual dues and subscriptions. The concept of national subscriptions will be modified in 2006, but it will be critical for the UICC to continue to receive generous financial support from its members to ensure a stable organisational future and to engage in strategic activities. A large number of donors (see page 40) also contributed significantly to UICC s finances. On behalf of UICC we take this opportunity to express our gratitude to all our supporters, without whom UICC could not perform its many activities. UICC: International Union Against Cancer The International Union Against Cancer (UICC) is devoted exclusively to all aspects of the worldwide fight against cancer. Its objective is to advance scientific and medical knowledge in research, diagnosis, therapy, and prevention of cancer and to promote all other aspects of the campaign against cancer throughout the world. Particular emphasis is placed on professional and public education. Founded in 1933, UICC is a non-governmental, independent association of more than 270 member organisations in over 80 countries. Members are voluntary cancer leagues and societies, cancer research and treatment centres and, in some countries, ministries of health. UICC is nonprofit, non-political and non-sectarian. Its headquarters are in Geneva, Switzerland. It creates and carries out programmes around the world in collaboration with hundreds of volunteer experts. It works in four strategic directions: prevention and early Tax status detection, tobacco control, knowledge transfer, and capacity building. Supported by membership dues, national subscriptions, grants and donations, its annual budget is about US$ 5 million. UICC is governed by its members through a General Assembly, which, beginning in 2006, will meet every two years. Responsibility for programme structure and implementation will move from the present Council and Executive Committee to a Board of Directors, elected at the General Assembly in 2006. UICC organises a World Cancer Congress (from 2006, every two years) as well as annual symposia, workshops and training courses. It publishes the International Journal of Cancer (30 issues per year), UICC enews (every second month), bloom, the newsletter of Reach to Recovery International (twice yearly), a Calendar of International Cancer Conferences (twice yearly), and technical reports, textbooks, and manuals. The International Union Against Cancer is a non-profit, international, non-governmental organisation governed in accordance with the articles 60 to 79 of the Swiss Civil Code. As a non-profit organisation devoted to the public interest, the Union has been exempted from income taxes by the Swiss tax authorities. This exemption is renewable every five years and will be renewed in 2006. Financial Report UICC
38 Putting cancer on the global agenda
Putting cancer on the global agenda 39 Balance Sheet as at 31 December 2005 in US Dollars Assets Unrestricted: Cash equivalents: Current accounts Time deposits Accounts receivable: Membership dues, net Related parties Other Prepaid expenses Financial investments Fixed assets, net TOTAL Donor Restricted: Receivable from unrestricted funds Liabilities and Fund Balances Unrestricted: Accounts payable and accrued expenses: Related parties Other Due to restricted funds Reserve for restricted currencies Other liabilities Translation difference Statutory reserve Fund balance 2005 1,070,173 2,353,048 1,567 1,652 22,168 4,670 750,000 44,598 4,247,876 2,488,455-149,421 2,488,455 12,188 650,183 20,089 200,000 727,540 2004 479,797 2,431,408 23,211 5,394 286,535 28,576 500,000 33,236 3,788,157 1,559,032 15,770 390,920 1,559,032 13,407 900,111 (6,361) 150,000 765,278 Auditors letter of recommendation Balance Sheet TOTAL 4,247,876 3,788,157 Donor Restricted: Trust funds 2,488,455 1,559,032 Income restricted & unrestricted 2005 USD 6,893,877 Expenditure restricted and unrestricted 2005 USD 5,952,193 7% 10% 16% 21% 60% 17% Strategic programme activities 69% Strategic programme activities Information and publications Membership dues Other Information and publications Administration and membership services The accounts, as presented, have been audited by Deloitte SA, Geneva, Switzerland. A complete set of the financial statements for 2005 may be obtained on request from UICC headquarters in Geneva.
40 Putting cancer on the global agenda UICC Contributors 2005 Amount USD Sanofi-aventis, France 908,872 American Cancer Society 577,971 Centers for Disease Control & Prevention, USA 483,518 Cancer Research UK 297,929 Pfizer, USA 285,000 National Cancer Institute, USA 280,000 John Wiley & Sons, USA 195,000 Dreyfusbank, Switzerland 160,000 Bristol-Myers Squibb, USA 142,488 Japan National Committee for UICC 140,000 Novartis, Switzerland 105,963 QUIT, UK 74,377 Dutch Cancer Society 64,609 National League Against Cancer, France 50,932 Mobile Manufacturers Forum (MMF), Belgium 49,545 GSM Association, Ireland 49,355 Office Fédérale de la Santé Publique, Switzerland 48,000 Swedish Cancer Society 47,232 Oncology Nursing Society, USA 30,000 C-Change, USA 30,000 American Society of Clinical Oncology 30,000 National Cancer Institute, Canada 28,000 Swiss Cancer League 25,000 Cancer Council Australia 22,180 Deutsche Krebshilfe/Mildred Scheel Foundation, Germany 20,000 Italian Association for Cancer Research 18,000 European Commission 14,502 Comité national contre le tabagisme, France 11,630 Danish Cancer Society 11,000 World Health Organization 10,500 Susan G Komen Breast Cancer Foundation, USA 10,000 Israel Cancer Association 7,000 Finnish Cancer Society 6,214 Various donations 9,563 Roll of Honour 8,763 Relay For Life 7,340 Royalties John Wiley & Sons, USA 500,050 Indirect contributors Barmer Ersatzkasse, Germany British Medical Journals, UK Campaign for Tobacco-Free Kids Cancer Council Australia Centers for Disease Control and Prevention, USA Centre for Chronic Disease Prevention and Control, Canada Credit Suisse Group Deutsches Krebsforschungszentrum, Germany Deutsche Krebsgesellschaft, Germany Federal Minstry of Health (BMG), Germany Framework Convention Alliance Hellenic Association of Women with Breast Cancer, Greece Junta Valenciana de la Asociacion Española contra el cancer National League Against Cancer, France Norwegian Cancer Society Office fédéral de la santé publique, Switzerland Oncology Nursing Society, USA Reach to Recovery, South Africa Sanofi-aventis Global Oncology Singapore Cancer Society Society of Volunteers Against Cancer, Greece Contributing suppliers Deloitte, Switzerland Gyro Group, Switzerland Sun Microsystems, Switzerland
Corporate supporters UICC is grateful to the corporate members and donors who contributed to our work in 2005. Many of the activities described in this annual report would not have happened without their generous support. sanofi-aventis John Wiley & Sons Pfizer Bristol-Myers Squibb Novartis Oncology Mobile Manufacturers Forum GSM Association Corporate membership is open to leaders of the medical supply and technology, pharmaceutical, biotechnology and health publishing industries and other private sector companies.